Nanoviricides (NNVC) Income from Continuing Operations (2010 - 2026)
Nanoviricides (NNVC) posted Income from Continuing Operations of 2030218.0 for Q1 2026, up 9.09% sequentially from 2233174.0 in Q4 2025, and up 9.74% YoY from 1850080.86 in Q1 2025.
Nanoviricides (NNVC) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Nanoviricides has reported Income from Continuing Operations for 17 years, with the latest figure at 2030218.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 9.74% year-over-year to 2030218.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8175684.0 (up 17.15% YoY) and the FY2025 annual result came in at 9618916.0, down 12.29% from the prior year.
- Income from Continuing Operations advanced to 2030218.0 in Q1 2026 per NNVC's latest filing, from 2233174.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1570642.0 in Q3 2022 and troughed at 3676373.0 in Q2 2023.
- A 5-year average of 2140364.94 and a median of 2030218.0 in 2026 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations tumbled 106.54% in 2023, then jumped 43.28% in 2025.
- Over 5 years, Income from Continuing Operations stood at 1745134.0 in 2022, then dropped by 25.95% to 2198071.0 in 2023, then gained by 6.32% to 2059200.0 in 2024, then dropped by 8.45% to 2233174.0 in 2025, then advanced by 9.09% to 2030218.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2030218.0, 2233174.0, and 1796689.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | -2.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.03 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -2.12 Mn |
| Mar 31, 2025 | -2.25 Mn |
| Dec 31, 2024 | -2.06 Mn |
| Sep 30, 2024 | -3.17 Mn |
| Jun 30, 2024 | -2.39 Mn |
| Mar 31, 2024 | -1.91 Mn |
| Dec 31, 2023 | -2.20 Mn |
| Sep 30, 2023 | -1.97 Mn |
| Jun 30, 2023 | -3.68 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -1.75 Mn |
| Sep 30, 2022 | -1.57 Mn |
| Jun 30, 2022 | -1.78 Mn |
| Mar 31, 2022 | -1.79 Mn |
| Dec 31, 2021 | -1.92 Mn |
| Sep 30, 2021 | -2.61 Mn |
| Jun 30, 2021 | -2.07 Mn |